Page 35 - 北京京煤集团总医院第十届·2022学术年会论文集

北京京煤集团总医院 第十届·2022 学术年会论文集

[6] Giannini F, Latib A, Jabbour RJ, et al. Comparison of paclitaxel drugeluting balloon and

paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients - results from

the BELLO (balloon elution and late loss optimization) trial[J]. Cardiovasc Revasc Med, 2017,
18:4-9.

[7] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC / EACTS Guidelines on myocardial
revascularization. The task force on myocardial revascularization of the European Society of

Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)[J]. GItal

Cardiol (Rome), 2019, 20:1S-61S.

[8] Narula J, Nakano M, Virmani R, et al. Histopathologic characteristics of atherosclerotic

coronary disease and implications of the findings for the invasive and noninvasive detection of

vulnerable plaques[J]. J Am Coll Cardiol, 2013, 61:1041-1051.

[9] Vos NS, van der Schaaf RJ, Amoroso G, et al. Revascularization with paclitaxel‐coated

balloon angioplasty versus drug‐eluting stenting in acute myocardial infarction‐a randomized

controlled trial: rationale and design of the REVELATION trial[J]. Catheter Cardiovasc Interv,

2016, 87(7):1213‐1221.

[10] Vos NS, Dirksen MT, Vink MA, et al. Safety and feasibility of a PAclitaxel‐eluting balloon
angioplasty in primary percutaneous coronary intervention in Amsterdam (PAPPA): one‐year

clinical outcome of a pilot study[J]. Euro Intervention, 2014, 10(5): 584‐590.

- 30 -